View : 64 Download: 0

Long-term rivaroxaban for the treatment of acute venous thromboembolism in patients with active cancer in a prospective multicenter trial

Title
Long-term rivaroxaban for the treatment of acute venous thromboembolism in patients with active cancer in a prospective multicenter trial
Authors
Yhim, Ho-YoungChoi, Won-IlKim, Sung-HyunNam, Seung-HyunKim, Kyoung HaMun, Yeung-ChulOh, DoyeunHwang, Hun-GyuLee, Keun-WookSong, Eun-KeeKwon, Yong ShikBang, Soo-Mee
Ewha Authors
문영철
SCOPUS Author ID
문영철scopus
Issue Date
2019
Journal Title
KOREAN JOURNAL OF INTERNAL MEDICINE
ISSN
1226-3303JCR Link

2005-6648JCR Link
Citation
KOREAN JOURNAL OF INTERNAL MEDICINE vol. 34, no. 5, pp. 1125 - 1135
Keywords
NeoplasmsRecurrenceRivaroxabanVenous thromboembolismTherapeutics
Publisher
KOREAN ASSOC INTERNAL MEDICINE
Indexed
SCIE; SCOPUS; KCI WOS scopus
Document Type
Article
Abstract
Background/Aims: Limited data are available regarding the efficacy of rivaroxaban for the treatment of cancer-associated venous thromboembolism (VTE). The aim of this study was to evaluate the effectiveness and safety of rivaroxaban for the treatment of VTE in active cancer patients. Methods: In this prospective, multicenter, open-label trial (NCT01989845), we enrolled patients with active cancer and objectively diagnosed lower-extremity deep vein thrombosis, pulmonary embolism (PE), or both from November 2013 to June 2016. Active cancer was defined as a histologically confirmed malignancy, which was diagnosed or treated within the previous 6 months, or as a recurrent/metastatic cancer. Patients received oral rivaroxaban 15 mg twice daily for first 3 weeks, followed by 20 mg once daily for 6 months. The primary outcome was the symptomatic recurrent VTE and the secondary outcomes included any recurrent VTE, major or clinically relevant non-major (CRNM) bleeding events, and overall mortality. All study outcomes were validated by blinded central adjudication. Results: Of 124 patients enrolled, 110 (88.7%) had solid cancer, 93 (75.0%) had metastatic disease, and no (88.7%) were receiving chemotherapy or radiotherapy. During the 6-month study period, seven patients experienced symptomatic recurrent VTE (cumulative incidence, 5.9%), and two patients experienced incidental recurrent PE (cumulative incidence of any recurrent VTE, 7.6%). Major bleeding events occurred in six patients (cumulative incidence, 5.3%) and CRNM bleeding events in 11 patients (cumulative incidence, 10.2%). Twenty-eight patients (overall mortality, 24.0%) died. Conclusions: Rivaroxaban is effective and safe for the treatment of VTE in patients with active cancer.
DOI
10.3904/kjim.2018.097
Appears in Collections:
의과대학 > 의학과 > Journal papers
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE